{"doi":"10.1093/rap/rkab051","title":"Rituximab for interstitial pneumonia with autoimmune features at two medical centres","abstract":"OBJECTIVES: Many patients with interstitial lung disease (ILD) have autoimmune manifestations but do not meet criteria for a systemic rheumatic disease. A subset meets criteria for interstitial pneumonia with autoimmune features (IPAF) and have ILD requiring therapy. We conducted a multicentre observational study to examine the use of rituximab (RTX) in IPAF. METHODS: Patients from Mass General Brigham (MGB) and University of Chicago Medicine (UCM) were included if they were ≥18 years old, met the 2015 classification criteria for IPAF and were treated with RTX. Clinical improvement was defined as improvement in four out of four domains at 1 year after RTX initiation: documented clinician global assessment; oxygen requirement; need for respiratory-related hospitalization; and survival. RESULTS: At MGB, 36 IPAF patients (mean age 61 years, 44% female) were treated with RTX. At 1 year, 18 (50%) were clinically improved, 12 (33%) were stable, and 6 (17%) died from progressive respiratory failure. At UCM, 14 IPAF patients (mean age 53 years, 71% female) were treated with RTX. At 1 year, eight (57%) were improved, two (14%) were stable, three (21%) died from progressive respiratory failure, and one (7%) was lost to follow-up. Two patients experienced minor infusion reactions, and two patients discontinued therapy owing to adverse events (infections). CONCLUSION: In patients with IPAF treated with RTX at two medical centres, the majority (40 [80%]) demonstrated improvement/stability at 1 year. These findings call for prospective studies, including randomized clinical trials, to determine the risks, benefits and cost effectiveness of RTX in IPAF.","journal":"Rheumatology Advances in Practice","year":2021,"id":184213,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9507,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":553610,"name":"Iazsmin Bauer Ventura","orcid":"0000-0003-1306-4241","position":1,"is_corresponding":false},{"id":282414,"name":"Marcy B. Bolster","orcid":"0000-0002-5413-9345","position":2,"is_corresponding":false},{"id":332666,"name":"Flavia V. Castelino","orcid":"0000-0001-9862-0299","position":3,"is_corresponding":false},{"id":599750,"name":"Amita Sharma","orcid":"0000-0002-2510-4805","position":4,"is_corresponding":false},{"id":106867,"name":"Brent P. Little","orcid":"0000-0001-6657-8241","position":5,"is_corresponding":false},{"id":285949,"name":"Ayodeji Adegunsoye","orcid":"0000-0002-7015-9610","position":6,"is_corresponding":false},{"id":285957,"name":"Mary E. Strek","orcid":"0000-0002-7671-1023","position":7,"is_corresponding":false},{"id":236763,"name":"Hyon K. Choi","orcid":"0000-0002-2862-0442","position":8,"is_corresponding":false},{"id":282416,"name":"Sydney B. Montesi","orcid":"0000-0002-5724-6808","position":9,"is_corresponding":false},{"id":236759,"name":"Kristin M. D’Silva","orcid":"0000-0001-8370-4166","position":0,"is_corresponding":true}],"reference_count":37,"raw_metadata":null,"created_at":"2026-07-18T23:48:26.340498Z","pmid":"34755024","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}